A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Clinical trial NCT02316106 · COMPLETED
Trial details
- NCT number
- NCT02316106
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-20
- Primary completion
- 2023-06-02
- Enrollment
- 123
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.